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ABSTRACT
The overall survival for adults with malignant glioma (glioblastoma) remains 
poor despite advances in radiation and chemotherapy. One of the mechanisms by 
which cancer cells develop relative resistance to treatment is through de-regulation 
of endoplasmic reticulum (ER) homeostasis. We have recently shown that ABCG1, 
an ATP-binding cassette transporter, maintains ER homeostasis and suppresses ER 
stress-induced apoptosis in low-grade glioma. Herein, we demonstrate that ABCG1 
expression is increased in human adult glioblastoma, where it correlates with poor 
survival in individuals with the mesenchymal subtype. Leveraging a mouse model 
of mesenchymal glioblastoma (NPcis), shRNA-mediated Abcg1 knockdown (KD) 
increased CHOP ER stress protein expression and resulted in greater NPcis glioma 
cell death in vitro. Moreover, Abcg1 KD reduced NPcis glioma growth and increased 
mouse survival in vivo. Collectively, these results demonstrate that ABCG1 is critical 
for malignant glioma cell survival, and might serve as a future therapeutic target for 
these deadly brain cancers.
INTRODUCTION
Brain tumors represent the fourth leading cause 
of cancer-related death in adults, where high-grade glial 
neoplasms (malignant gliomas) predominate [1]. These 
malignant gliomas are classified by the World Health 
Organization (WHO) as grade III (anaplastic astrocytoma, 
anaplastic oligodendroglioma, and anaplastic mixed 
oligoastrocytoma) or IV (glioblastoma) astrocytomas, 
commonly occurring in individuals between the ages of 
45 and 75 years [2]. Unfortunately, survival following 
the diagnosis of a glioblastoma is dismal, with most 
patients dying within 12–16 months despite aggressive 
surgical, radiation, and chemotherapy management 
[1, 3]. Since these cancers are thought to be maintained 
by cells with stem cell-like properties (glioma stem cells; 
GSCs), intense focus over the past decade has centered 
on understanding the critical pathways that govern GSC 
growth and differentiation [4, 5]. 
In this regard, a large number of studies have 
revealed that GSCs are capable of long-term self-renewal, 
multi-lineage differentiation, and the generation of 
histologically-similar tumors following implantation 
into immunocompromised rodent brains [6]. Most often 
identified by their expression of the prominin-1 cell 
surface marker, CD133 [6, 7], GSCs can be enriched by 
antibody-mediated isolation, and shown to possess unique 
properties such as radioresistance and chemoresistance 
not shared with normal brain neural stem cells (NSCs) 
[8–10]. Another of these markers is the ABCG2 protein, 
which identifies the “side population”, a subset of stem 
cells hypothesized to be enriched for cancer propagation 
abilities [9, 11].
Similar to ABCG2, ABCG1 belongs to a large 
family of ATP-binding cassette proteins involved in 
cellular transport [12, 13], where it mainly directs lipid 
transport [14, 15]. In this regard, we recently leveraged 
a low-grade glioma mouse model of Neurofibromatosis 
type 1 (NF1)-associated optic glioma to identify and 
characterize low-grade glioma (LGG) cancer stem cells 
(LG-GSCs) [16]. Similar to their malignant glioma 
counterparts, these LG-GSCs were capable of long-term 
self-renewal, multi-lineage differentiation, and forming 
low-grade glioma-like lesions following explantation 
into immunocompetent mice. However, ABCG2 was not 
highly expressed in these murine LG-GSCs, consistent 
with an absence of a side population following Hoechst 
33342 flow cytometry. Instead, ABCG1 was highly 
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enriched in both murine and human LG-GSCs relative to 
their non-neoplastic NSC counterparts, where it served 
to protect these cells from ER stress-mediated cell death 
(apoptosis).
Based on the controversial use of ABCG2 as a 
marker of CSCs [11] and the recent identification of 
ABCG1 as a critical mediator of LG-GSC survival, we 
sought to determine whether ABCG1 was important 
for high-grade (glioblastoma) survival. In this report, 
we demonstrate that ABCG1 expression negatively 
correlates with survival in patients with glioblastoma of 
the mesenchymal subtype. Leveraging a mouse model 
of mesenchymal glioblastoma (NPcis), characterized by 
Nf1 and Trp53 loss, we show that shRNA-mediated Abcg1 
knockdown increases ER stress-induced apoptosis in vitro 
as well as improves the survival of immunocompetent 
mice with glioblastoma in vivo. Collectively, these results 
establish ABCG1 as another potential biomarker for 
high-grade glioma survival relevant to future brain tumor 
therapeutic targeting.
RESULTS
Glioblastoma ABCG1 expression is associated 
with reduced patient survival
We have recently shown that human low-grade 
(pilocytic astrocytoma) glioma specimens exhibit 
increased ABCG1 expression [16]. To determine 
whether ABCG1 expression was similarly increased in 
human glioblastoma specimens, two sets of experiments 
were performed. Using the one available GEO dataset 
containing normal reference tissue (astrocytes; 
GSE15824), we found that ABCG1 expression was 
increased in glioblastoma tumors (697 ± 554, 230913_at 
probe set; 428 ± 305, 232081_at probe set) relative to 
astrocytes (11.5 ± 1.1, 230913_at probe set; 13.9 ± 8.1, 
232081_at probe set). Similarly, increased ABCG1 
immunoreactivity was observed in representative tumor 
specimens from human patients with glioblastoma (n = 16) 
relative to normal brain controls (n = 7) (Figure 1A and S1). 
Next, we sought to determine whether ABCG1 
expression was associated with clinical outcome (overall 
survival) in patients with high-grade glioma (GSE16011), 
the majority of whom did not receive prior chemotherapy. 
Using a total of 159 glioblastoma patients dichotomized by 
the median of ABCG1 expression, there were no significant 
survival differences between patients harboring gliomas 
with low versus high ABCG1 gene expression (Figure 1B). 
However, when the analysis was stratified by glioblastoma 
molecular subtype, high ABCG1 expression correlated 
with shorter overall survival only in the mesenchymal 
subgroup (Figure 1C), a subtype characterized by NF1 
gene mutation [17]. Moreover, using multivariate Cox 
hazard regression analysis with adjustment for both age 
and Karnofsky Performance Score (KPS), the negative 
prognostic value of ABCG1 expression in mesenchymal 
GBM patient survival remained significant (P = 0.017; 
Figure 1D). Together, these findings demonstrate increased 
ABCG1 expression in human malignant gliomas, where it 
is associated with reduced survival in patients harboring 
the mesenchymal glioblastoma subtype. 
Abcg1 knockdown decreases glioblastoma cell 
growth in vitro
In the glioblastoma mesenchymal molecular 
subtype, NF1 loss is frequently associated with TP53 
mutation [17]. Consistent with this observation, mice 
harboring germline inactivating mutations in both the 
Nf1 and Trp53 genes residing on the same chromosome 
(NPcis mice) spontaneously develop high-grade gliomas 
[18, 19]. Moreover, derivative glioma cells from these 
NPcis mouse tumors exhibit bi-allelic loss of the Nf1 and 
Trp53 genes in addition to increased PDGFRα expression, 
molecular features also observed in human mesenchymal 
glioblastomas [17, 20, 21]. Given the correlation between 
ABCG1 expression and overall survival in patients 
with mesenchymal subtype glioblastoma, we sought 
to determine whether ABCG1 might be important for 
NPcis glioma growth using lentivirus-mediated shRNA 
knockdown in two independently-generated NPcis high-
grade glioma cell lines (K1861 and K4622; [22]). First, 
we confirmed Abcg1 knockdown using two distinct 
shRNA constructs by Western blotting (Figure 2A; ~50% 
protein reduction). Following Abcg1 knockdown, K1861 
cells exhibited morphological changes (e.g., rounding) 
suggestive of cell death (Figure 2B). Consistent with 
these cellular changes, reduced cell growth (% Ki67+ 
cells; Figure 2C) and increased apoptosis was observed 
(% cleaved caspase-3+ cells; Figure 2C) relative to shRNA 
controls. Identical results were also observed using the 
K4622 high-grade glioma cell line (Figure S2). 
Abcg1 knockdown increases ER stress and 
glioblastoma cell apoptosis
Since Abcg1 confers a survival advantage to LG-
GSCs by suppressing ER stress [16], we examined the 
expression of BiP and CHOP, two markers of ER stress. 
Following Abcg1 knockdown (45–54% protein reduction) 
in K1861 and K4622 glioblastoma cells, there was 
increased CHOP expression (2.3 and 3-fold, respectively) 
and caspase-3 cleavage (1.5 and 2.2-fold, respectively) 
relative to controls (Figure 3). However, in contrast to 
LG-GSCs, there was no change in BiP expression upon 
Abcg1 reduction.
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Abcg1 knockdown reduces glioma growth and 
mouse survival in vivo
To determine whether Abcg1 knockdown also 
decreases glioma growth in vivo, 5.0 × 104 K1861 
glioblastoma cells were stereotactically injected in the 
right striatum of 3-week-old C57Bl/6J mice. Since these 
K1861 cells were transduced with a lentiviral vector 
expressing green fluorescent protein and firefly luciferase, 
tumor growth could be monitored by live bioluminescence 
imaging (BLI). We specifically chose to employ the 
K1861 glioblastoma for these in vivo experiments, based 
on previous studies demonstrating that K1861-engrafted 
mice develop large and aggressive intracranial tumors 
[19, 23]. Whereas all engrafted mice harbored brain 
tumors, there was reduced tumor growth by BLI in the two 
K1861 Abcg1 shRNA groups (n = 10 mice/group) relative 
to control shRNA K1861-implanted mice (n = 10 mice) at 
28 days post-injection (Figure 4A) and the bioluminescent 
signal was significantly reduced in both Abcg1 shRNA 
groups relative to control shRNA K1861-implanted mice 
(#1, p = 0.042; #2, p = 0.0098; Figure 4B). Over the 
120 days of observation, mice in the shRNA control group 
became ill and had to be euthanized (median survival 
= 37 days). However, in striking contrast, mice receiving 
Abcg1-shRNA K1861 glioblastoma cells had median 
survivals of 64 (P < 0.0001) and 98 (P < 0.0001) days, 
respectively (Figure 4C). While shAbcg1-#2 was slightly 
more effective at reducing Abcg1 protein expression 
than shAbcg1-#1 (15% versus 30% of shLacZ levels), 
which might account for the observed lower BLI signal 
observed in mice receiving 1861 cells with shAbcg1-#2 
versus shAbcg1-#1 (P = 0.0226), there was no difference 
in survival (P = 0.1426). 
To determine whether Abcg1 knockdown resulted 
in increased glioblastoma apoptosis in vivo, Ki67 and 
TUNEL immunostaining were performed on the tumors 
following euthanasia. Consistent with the above in vitro 
findings, shAbcg1 K1861 tumors had reduced Abcg1 
protein expression and fewer Ki67+ cells relative to 
Figure 1: Abcg1 expression is associated with poor overall survival in the mesenchymal glioblastoma molecular subtype. 
(A) A representative specimen from one adult with a glioblastoma reveals increased ABCG1 expression relative to one representative age-
matched control brain. Scale bar, 50 μm. (B) Prognostic effect of ABCG1 (high vs. low) in all patients and within each subtype. (C) Kaplan-
Meier analysis demonstrates that increased ABCG1 expression negatively correlated with overall survival in patients with the mesenchymal 
glioblastoma subtype (p = 0.004) in GSE16011. (D) In GSE16011, while both age (P = 0.0023) and KPS (P = 0.0037) are associated with 
overall survival, multivariate analysis shows that high ABCG1 expression is a strong predictor of poor patient survival, independent of age 
and KPS (P = 0.017).
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Figure 2: Abcg1 knockdown reduces NPcis glioma cell growth in vitro. (A) shRNA-mediated Abcg1 knockdown in K1861 
NPcis glioma cells. (B) NPcis cells 6 days post-infection with shAbcg1 or control shLacZ virus. Following Abcg1 knockdown, there was 
(C) reduced cell growth (% Ki67+ cells) and increased apoptosis (% cleaved caspase 3+ cells). Scale bar, 50 μm. Error bars denote mean ± SD. 
(*) p < 0.05.
Figure 3: Abcg1 knockdown increases the ER stress response. shRNA-mediated Abcg1 knockdown in K1861 and K4622 
glioblastoma cells increased CHOP and cleaved caspase-3, but not BiP, expression. 
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controls (Figure 5). In addition, shAbcg1 K1861 tumors 
had increased cell death (TUNEL+ cells). Collectively, 
these findings establish Abcg1 as a mediator of ER stress-
mediated apoptosis and survival in high-grade glioma. 
DISCUSSION
Adaption to ER stress represents one protective 
mechanism for sustaining tumor cell growth and 
survival in the setting of hypoxia, low glucose levels, or 
chemotherapeutic drug exposure [24, 25]. While little is 
known about ABCG1 in cancer, we demonstrate for the 
first time that ABCG1 is expressed in both murine and 
human glioblastoma, where its expression correlates with 
overall patient survival. Interestingly, ABCG1 expression 
was not associated with survival in patients with all 
molecular subtypes of glioblastoma; however, there was 
a strong correlation between poor patient survival and 
high ABCG1 RNA expression in tumors classified in the 
mesenchymal GBM subtype. In this subtype, one of the 
signature genetic changes is mutation of the NF1 tumor 
suppressor gene [17], which is intriguing, given the 
prior identification of ABCG1 as a uniquely upregulated 
transcript in GSCs originating from a mouse model of 
low-grade glioma harboring biallelic Nf1 gene inactivation 
[16, 26]. Importantly, increased Abcg1 expression does not 
Figure 4: Abcg1 knockdown reduces tumor growth in vivo. (A) Representative bioluminescence images of tumors in engrafted 
mice from control shLacZ and shAbcg1 groups (#1, #2) at 28 day post-transplantation were shown. (B) Photon flux of alive mice in all 
groups at 4 weeks post-transplantation. Relative to shLacZ-K1861 implanted mice, C57BL/6 mice receiving shAbcg1-K1861 tumors 
had reduced bioluminescence signal (#1, p = 0.042; #2, p = 0.0098). Error bars denote mean ± SEM. (C) Kaplan-Meier survival analysis 
reveals that mice transplanted with shAbcg1 K1861 NPcis cells exhibit longer survival than those injected with control (shLacZ) NPcis cells 
(log-rank test; p < 0.0001).
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result from Nf1 loss directly, but is rather a consequence of 
GSC development. In this regard, only optic glioma stem 
cells, but not Nf1-deficient NSCs, exhibit increased Abcg1 
expression [16]. While it is currently not known how 
ABCG1 expression is regulated, a recent study conducted 
in CHO cells implicated E3-ubiquitin ligases (HUWE1 
and NEDD4-1) in the post-translational regulation of 
ABCG1 protein stability and cholesterol export [27]. 
Formal demonstration of an ubiquitin ligase pathway 
that coordinately regulates neurofibromin and ABCG1 
expression in glioma warrants further investigation 
[28, 29].
Similar to our findings in LG-GSCs, reduced 
Abcg1 protein expression using two different shRNA 
targeting constructs in two independently-generated 
NPcis glioblastoma lines (K1861 and K4622) increased 
the expression of CHOP, a final effector of the ER stress 
response, and resulted in higher levels of tumor cell death 
by apoptosis. However, in contrast to optic glioma stem 
cells, some molecular elements of the ER stress pathway 
were not conserved in glioblastoma cells. In this regard, 
we did not observe any changes in BiP expression, PDI 
expression, or PERK phosphorylation (data not shown), 
suggesting that other ABCG1-dependent mechanisms 
for inducing ER stress may be operative. Further studies 
focused on additional ER stress pathways in glioblastoma 
are currently being explored.
The fact that attenuated ABCG1 expression 
significantly prolongs mouse survival following 
glioblastoma implantation supports a critical role for 
this protein in tumor maintenance. This in vivo effect 
was demonstrated both in terms of tumor growth 
(bioluminescence imaging and tumor proliferation) and 
apoptosis (TUNEL), reminiscent of reported effects of 
ABCG2 in high-grade brain tumors. In these studies, 
ABCG2 has been implicated in reduced brain penetration 
of enhancer of zeste homolog 2 (EZH2) inhibitors [30] 
as well as the anti-tumoral responses to PARP inhibitors 
(ABT-888) and temozolomide [31]. Moreover, ABCG2 
downregulation inhibits glioma stem cell migration and 
invasion [32, 33], where its expression partly dictates 
the behavior of the side population of high-grade GSCs 
[9, 34]. These exciting observations prompted recent 
discovery efforts to identify potential modulators of 
ABCG2 [35]. As the etiologic mechanisms responsible 
for ABCG1-mediated suppression of ER stress and glioma 
survival become elucidated [36–41], future therapeutic 
strategies designed to blocking these adaptations 
may improve treatment efficacy for this deadly brain 
malignancy. 
Figure 5: Abcg1 knockdown increases glioblastoma apoptosis in vivo. Glioma sections from control mice (shLacZ) reveal 
reduced Abcg1 immunostaining relative to mice harboring tumors with shAbcg1 knockdown. Following Abcg1 knockdown, there was 
decreased glioma growth (% Ki67+ cells) and increased apoptosis (% TUNEL+ cells). Error bars denote mean ± SD. (*) p < 0.05.
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MATERIALS AND METHODS
Cell lines and mice
Mouse malignant glioma NPcis cell lines, K1861 
and K4622, were derived from C57BL/6J Trp53+/−/Nf1+/− 
mice (Dr. Karlyne Reilly, National Cancer Institute)
[22]. These lines were maintained at 37˚C in 5% CO
2
 in 
Dulbecco’s modified Eagle medium containing 10% fetal 
bovine serum. All mouse procedures were performed in 
accordance with an approved Animal Studies protocol at 
Washington University.
Lentivirus infections
Prior to the lentiviral shAbcg1 infection, NPcis 
cells were transduced with lentiviral FUW-GL vector 
(Dr. Joshua Rubin) for bioluminescence imaging. Abcg1 
shRNA or control shLacZ-containing pLKO.1 plasmid 
was co-transfected with pMDLg/pRRE, pRSV-REV and 
pCMV-VSV-G into HEK293T cells using the FuGENE 
HD transfection reagent (Roche). NPcis cells were 
dissociated into single cells by trypsin and transduced with 
viral supernatants from HEK293T cells with polybrene 
(8 μg/mL) for 48 hours. The knockdown efficiency of 
the Abcg1 shRNA constructs was evaluated by Western 
blotting. Lentiviral constructs used are listed in Table S1. 
Western blotting
Western blotting was performed as previously 
reported [42] using the primary antibodies listed in Table S2. 
Intracranial injections
Injections were performed as previously described 
[43]. 3 to 5-week-old male wild-type C57BL/6J purchased 
from Taconic were used. NPcis cells were prepared in a 
2.5 × 104 cell/μL PBS solution and 2 μL (5 × 104) cells 
were sterilely implanted intracranially into the right 
side striatum using a stereotactic device (coordinates = 
posterior 3 mm from the bregma, lateral 1.5 mm (right), 
and depth 2.5 from dura mater). Mice were monitored and 
euthanized after neurological symptoms developed.
In vitro cell proliferation and death 
NPcis cells were trypsinized and plated onto 50 μg/
mL poly-D-lysine-coated and 10 μg/mL fibronectin-coated 
24-well plates in defined culture medium. After 24 hours, 
cells were fixed in 4% paraformaldehyde. Proliferating 
and apoptotic cells were detected using antibodies to Ki67 
and cleaved caspase-3, respectively. The percent of Ki67+ 
or cleaved caspase-3+ cells were determined as a percent 
of the total cell number (DAPI+ cells). 
Human specimens and immunostaining
The use of human subject materials was approved by 
the institutional review board of the Washington University 
School of Medicine. Sixteen intracranial glioblastomas 
(WHO grade IV) and seven surgically obtained brain 
control cases were identified. Corresponding formalin-
fixed paraffin-embedded blocks from the pathology 
archives were used for immunohistochemistry. Paraffin 
sections were processed [44] prior to staining with 
appropriate antibodies (Table S2). The TUNEL labeling 
was performed using a fluorescence-based in situ cell 
death detection kit (Roche Diagnostics). The numbers of 
Ki67+ and TUNEL-positive cells were counted within the 
tumors per surface area (0.1 mm2). 
Bioluminescence imaging
Animals were given 150 μg/mL D-luciferin 
(Gold Biotech) in PBS through intraperitoneal injection 
and imaged with a charge-coupled device (CCD) camera-
based bioluminescence imaging system (IVIS50; Perkin-
Elmer, Hopkinton, MA) with exposure time 10 secs - 
1minute, binning 8, field of view 12, f/stop 1, open filter. 
Signal was displayed as photons/sec/cm2/sr [45].
Survival outcome analyses 
The survival outcome analyses were performed 
on the GSE16011 dataset using the R package “RMS”. 
Each GBM sample (159 out of 276 total samples) was 
assigned to a TCGA subtype (Classical, Mesenchymal, 
Neural, or Proneural) based on the 10-nearest neighbors 
algorithm as previously described [46]. Kaplan-Meier 
survival plots were generated, along with log rank tests, 
to compare survival differences between the low/high-
expression groups. Multivariate Cox models were fitted 
to gene expression (binary format, as dichotomized by the 
median) with incorporation of classic clinicopathological 
parameters (e.g., TCGA molecular subtype, age and KPS) 
to assess the independent prognostic ability of the 
candidate gene by the adjusted hazard ratio and associated 
95% confidence interval (CI). Age and KPS were 
incorporated in the format of restricted cubic spline basis 
function with three knots in order to relax the linearity 
assumption.  
Statistical analysis
Each experiment was performed with samples from 
at least three independent groups. All data were processed 
and graphed in Prism GraphPad 6.0 with descriptive 
statistics calculated. The difference between experimental 
groups was assessed by one-way ANOVA.  Survival 
curves were generated by the Kaplan-Meier method, and 
the Log-rank (Mantel-Cox) test was used to compare 
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between/among treatments. All tests were two-sided with 
a significance level of 5% unless otherwise noted. 
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